SCLERO.ORG
Search
SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

June 2020 Scleroderma News

Older age onset of systemic sclerosis (SSc) - accelerated disease progression in all disease subsets. In this large registry, 25% of patients developed SSc at an age above 60 years with an increased frequency of limited cutaneous systemic sclerosis. PubMed, Rheumatology (Oxford), 04/24/2020. (Also see Causes of Scleroderma)

Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. IL-31/IL-31RA is confirmed as a candidate pro-fibrotic pathway, which may contribute to skin and lung fibrosis in a subset of scleroderma patients. PubMed, Rheumatology (Oxford), 05/04/2020. (Also see Interleukins)

Long-standing morphea and the risk of squamous cell carcinoma of the skin (cSCC). Fibrosis, inflammation and chronic ulcerations may eventually promote skin neoplasms; morphea is therefore a rare but established risk factor for cSCC. PubMed, J Dtsch Dermatol Ges, 05/04/2020. (Also see Causes of Morphea)

Systemic Sclerosis and Vaccinations. Age over 65 years old, interstitial lung disease, and ongoing immunosuppressive therapy were significantly related with acceptance to both vaccinations using univariate analyses. PubMed, Vaccines (Basel), 2020 Apr 28;8(2). (Also see Vaccinations)

Systemic sclerosis (SSc) and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. SSc patients are a great challenge for the physician to achieve an effective protective strategy or, when infected, to optimise a real-time treatment as suggested by the rapidly evolving guidelines. BMJ Journals, Ann Rheum Dis, 04/29/2020. (Also see Pulmonary Fibrosis)

Effect of a tailored home-based exercise program in patients with Systemic Sclerosis (SSc): a randomized controlled trial. This study indicates that in SSc patients a minimally supervised, home-based exercise program improves physical performance, quality of life and disability in comparison to usual care. PubMed, Scand J Med Sci Sports, 04/29/2020. (Also see Coping Strategies)

Effect of a monocyte chemoattractant protein-1 synthesis inhibitor on fibroblasts from patients with carpal tunnel syndrome (CTS). These results suggest that Bindarit in combination with SD208 may be beneficial as medical therapy for the subsynovial connective tissues fibrosis associated with CTS. PubMed, J Orthop Sci, 04/18/2020. (Also see Hand and Joint Involvement and Fibroblasts)

Ultraviolet A1 phototherapy for the treatment of localized scleroderma. UVA1 successfully ameliorated sclerotic lesions, including morphea, linear scleroderma and morphea lesions in a patient with limited cutaneous systemic sclerosis. PubMed, J Dermatol, 05/08/2020. (Also see Morphea Treatments)

Comparative analysis of affected and unaffected areas of systemic sclerosis (SSc) skin biopsies by high-throughput proteomic approaches. We identified a number of proteins and pathways that might be involved in SSc progression and pathogenesis. PubMed, Arthritis Res Ther, 2020 May 7;22(1):107. (Also see Skin Fibrosis)

Nailfold Videocapillaroscopy (NVC) is a Useful Tool to Recognize Definite Forms of Systemic Sclerosis (SSc) and Idiopathic Inflammatory Myositis in Interstitial Lung Disease Patients (ILD). NVC should be considered in the diagnostic assessment of ILD patients regardless of the presence of Raynaudís Phenomenon. PubMed, Diagnostics (Basel), 2020 Apr 25;10(5). (Also see Nailfold Videocapillaroscopy and Pulmonary Fibrosis Diagnosis)

Go to Scleroderma Medical News: May 2020
 

SCLERO.ORG was the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses from 1998 to 2021. It was a grassroots movement from the original Scleroderma from A to Z web site, which was founded by Shelley Ensz. We were a 501(c)(3) U.S.-based public charitable foundation. We closed this web site and our nonprofit agency in April 2021.

International Scleroderma Network (ISN)